FDA, Nivolumab and Bristol-Myers Squibb

FDA Approves Subcutaneous Nivolumab Across Existing Solid Tumor Indications
On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid tumor indications of the agent as monotherapy or monotherapy maintenance or in combination with chemotherapy or cabozantinib (Cabometyx). 1
Nivolumab by Bristol-Myers Squibb for Neuroendocrine Tumors: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Neuroendocrine Tumors.
Bristol Myers announces FDA approval of Opdivo Qvantig injection
Squibb announced that the U.S. FDA granted approval for Opdivo Qvantig injection for subcutaneous use, a combination product
Bristol-Myers Squibb : FDA Approves Opdivo Qvantig For Subcutaneous Use In Adult Solid Tumors
Bristol Myers Squibb (BMY) announced Friday that the U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo.
Bristol Myers Squibb Stock In Focus After FDA Approves Cancer Drug: Retail Sentiment Brightens
Shares of Bristol Myers Squibb ($BMY) were in the spotlight on Friday after the U.S. Food and Drug Administration approved an injectable version of the pharmaceutical major’s cancer drug Opdivo. Opdivo is reportedly part of PD-1 inhibitors class of drugs,
Contract Pharma4h
FDA Approves BMS’ Opdivo Qvantig with Halozyme’s ENHANZE Technology
Becomes the first subcutaneously administered PD-1 inhibitor.
Pharmabiz13h
US FDA approves Opdivo Qvantig injection, for subcutaneous use in most previously approved adult, solid tumour Opdivo indications
US FDA approves Opdivo Qvantig injection, for subcutaneous use in most previously approved adult, solid tumour Opdivo indications: Princeton, New Jersey Monday, December 30, 2024, ...
Too Old to Operate20d
Survival Up With Nivolumab + Ipilimumab Versus Chemo for Metastatic CRC
For patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer ...
Targeted Oncology2d
Top 10 Genitourinary Cancer Advances in 2024
In January 2024, the FDA approved erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial ...
Oncology Nurse Advisor4h
Liver Metastasis Does Not Impact Efficacy of ICIs in Gastroesophageal Cancer, Data Suggest
More research is needed to refine treatment strategies and identify predictive biomarkers for patient selection, according to researchers.
Renal & Urology News27d
Adding Nivolumab to Tivozanib Provides No Benefit in RCC After Prior ICI
Results from the phase 3 TiNivo-2 trial suggest that immune checkpoint inhibitor rechallenge should generally be discouraged ...
manilatimes4h
CARsgen Announces Positive Topline Results from China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T (Satri-cel)
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...